jueves, 12 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 5, 2026

LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?

View original at finance.yahoo.com
LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock? Eli Lilly and Company’s LLY stock has risen 28% in the past three months…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Novo Nordisk will advance next-generation obesity candidate amycretin into late-stage development, both as injection and oral pill, with phase III program planned to initiate during first quarter of 2026

    80% confidence

  • Mounjaro and Zepbound account for more than 50% of the company's total revenues

    80% confidence

  • Eli Lilly is a great stock to have in one's portfolio, given its significant price appreciation, product and pipeline portfolio, robust growth prospects and bullish analyst sentiment

    80% confidence

  • The obesity market is huge and multiple players can co-exist

    80% confidence

  • Eli Lilly is a Zacks Rank #1 (Strong Buy) stock

    80% confidence

  • Eli Lilly expects data readouts from three phase III studies on retatrutide for treating obesity in the second half of 2026

    80% confidence

  • Mounjaro and Zepbound are expected to continue to see strong demand in 2026

    80% confidence

  • Structure Therapeutics expects to initiate late-stage program of aleniglipron in obesity around mid-2026

    80% confidence

  • Eli Lilly plans to file regulatory applications for orforglipron in type II diabetes in the first half of 2026

    80% confidence

  • Despite NVO having the lead in the oral obesity market, Lilly may be able to close the gap fast once orforglipron is approved by the FDA in 2026

    80% confidence

  • Eli Lilly expects new drugs (Mounjaro, Zepbound, Omvoh, Jaypirca, Ebglyss and Kisunla), along with expanded use of existing drugs, to drive sales growth in 2026

    80% confidence

  • Novo Nordisk expects to launch the Wegovy pill in early January 2026

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,565 documentos fuente archivados
Consulta estos datos → isubstrate.com
LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock? — Source | Via News | es.VIA.NEWS